Home Neuronal Signaling Dopamine Receptor agonist Levodopa For research use only.

Levodopa

Synonyms: L-DOPA

Levodopa(L-DOPA) is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), used to treat Parkinson's symptoms.

Levodopa Chemical Structure

Levodopa Chemical Structure

CAS No. 59-92-7

Purity & Quality Control

Levodopa Related Products

Signaling Pathway

Dopamine Receptor Signaling Pathways

Dopamine Receptor Signaling Pathway

Biological Activity

Description Levodopa(L-DOPA) is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), used to treat Parkinson's symptoms.
Targets
Dopamine receptor [1]
In vitro
In vitro

Levodopa produces at 25-200 μM concentrations a dose-dependent reduction of 3H-DA uptake in foetal rat midbrain cultures. Levodopa results in a decrease in the number of viable cells and tyrosine hydroxylase (TH) positive neurones, plus disruption of the overall neuritic network. [1] Levodopa induces dyskinesia in the absence of dopamine by excessive inhibition of neurons of the putamen-globus pallidus (GPe) projection and subsequent disinhibition of the globus pallidus (GPe). Levodopa results in a decrease in cytochrome oxidase messenger RNA expression in the globus pallidus (GPi). [2]
In Vivo
In vivo

Levodopa elicits the development of a variety of abnormal movements in monkeys with parkinsonism induced by the neurotoxin MPTP. Levodopa administrations result in an ectopic induction of the dopamine D3receptor expression in the CdPu in 6-OHDA-lesioned rats. [3] Levodopa (50 mg/kg) increases anandamide concentrations throughout thebasal ganglia via activation of dopamine D1/D2 receptors in intact rats. Levodopa produces increasingly severe oro-lingual involuntary movements which are attenuated by the cannabinoid agonist R(+)-WIN55,212-2 (1 mg/kg) in lesioned rats. [4] Levodopa administration reverses the up-regulation of D2 dopamine receptors seen in severely lesioned rats provided evidence that Levodopa reaches a biologically active concentration at the basal ganglia. [5]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05094011 Not yet recruiting
Idiopathic Parkinson''s Disease
Taiwan Mitochondrion Applied Technology Co. Ltd.
 March 1 2025 Phase 1
NCT06284629 Not yet recruiting
Parkinson Disease
Rigshospitalet Denmark|Odense University Hospital|Zealand University Hospital
 September 1 2024 Not Applicable
NCT05558189 Not yet recruiting
Parkinson Disease
Stanford University
 August 20 2024 Not Applicable
NCT06339034 Not yet recruiting
Parkinson Disease
State University of New York at Buffalo|The Cure Parkinson''s Trust
 June 2024 Phase 1|Phase 2

Chemical Information & Solubility

Molecular Weight 197.19 Formula

C9H11NO4

CAS No. 59-92-7 SDF Download Levodopa SDF
Smiles C1=CC(=C(C=C1CC(C(=O)O)N)O)O
Storage (From the date of receipt)

In vitro
Batch:

5%TFA : 6.03 mg/mL

DMSO : Insoluble ( Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Levodopa | Levodopa ic50 | Levodopa price | Levodopa cost | Levodopa solubility dmso | Levodopa purchase | Levodopa manufacturer | Levodopa research buy | Levodopa order | Levodopa mouse | Levodopa chemical structure | Levodopa mw | Levodopa molecular weight | Levodopa datasheet | Levodopa supplier | Levodopa in vitro | Levodopa cell line | Levodopa concentration | Levodopa nmr